Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Atea Reports $32.2 Million Third-Quarter Loss as HCV Trial Advances

None

Atea Pharmaceuticals (AVIR) reported a net loss of $32.2 million, or $0.40 per basic and diluted share, for the third quarter ended September 30, 2026. The company held $191.2 million in cash, cash equivalents and marketable securities at quarter-end.

The company reported positive Phase 3 C-BEYOND results for its bemnifosbuvir/ruzasvir regimen in hepatitis C and said Phase 3 C-FORWARD topline results remain expected in early 2027.

  • Research and development expense was $27.1 million, down from $38.3 million a year earlier.
  • General and administrative expense was $6.9 million, compared with $7.2 million in the prior-year quarter.
  • Atea entered a Hercules Capital credit facility of up to $200 million and drew $65 million at closing on November 6, 2026.
  • The company said its current resources are expected to fund planned operations into mid-2028.
  • C-BEYOND reported a 93.91% sustained virologic response rate for BEM/RZR versus 94.75% for Epclusa in the modified intent-to-treat population.
EARLY ACCESS
Receive AVIR Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$AVIR Hedge Fund Activity

We have seen 63 institutional investors add shares of $AVIR stock to their portfolio, and 54 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles